Healthcare Industry News: C.R. Bard
News Release - April 21, 2009
Covidien Files Patent Infringement Lawsuit over Davol's Mesh Fixation Device and ApplierNORTH HAVEN, Conn.--(HSMN NewsFeed)--Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against Davol, Inc., a wholly owned subsidiary of C.R. Bard, relating to its mesh fixation device and applier. The lawsuit contends that Davol’s recently released Sorbafix™ device infringes multiple claims of Covidien’s U.S. Patent Number 6,562,051.
“We will vigorously protect our intellectual property,” said Dave Motley, Global Surgical Franchise and Portfolio Management, Covidien.
The patent generally relates to a system for controllably discharging fasteners from an applicator. Covidien is asking the federal court to enjoin Davol from continuing to make and sell its Sorbafix™ device, as well as for compensatory damages.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.